CD19 and acute lymphoblastic leukemia: In pediatric and young adult acute lymphoblastic leukemia (ALL), CD19 CAR T-cells manufactured with a lentiviral vector with 4-1BB and CD3ζ costimulatory domains, the 1-year event free survival (EFS) was only 50% [12].